FDA peptide policy passes White House review, cleared for release

The White House this morning cleared the FDA's new peptides compounding policy for release, which can now be issued at any time. The policy passed White House review and is marked 'consistent with change' on the RegInfo database, with the review concluded Oct. 27. The FDA can now move toward issuing its interim peptide compounding policy, likely expanding access to certain peptides.

Detected & updated continuously · Source: Nebula